Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Individual target tophus response categories at patient’s final visit in the randomized trials a

From: Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy

Categories Pegloticase Pegloticase Placebo
  biweekly monthly  
(n= 62) (n= 64) (n= 29)
Total number of tophib 229 201 117
Response category, n (%)
  CR 57 (25) 30 (15) 2 (2)
  PR or MR 49 (21) 33 (16) 12 (10)
  SD 111 (49) 121 (60) 89 (76)
  PD 1 (0.4) 1 (0.5) 3 (3)
  Unable to evaluate 11 (5) 16 (8) 11 (9)
  1. aCR, complete response; MR, marked response; PD: progressive disease; PR, partial response; SD: stable disease. bTotal tophi includes both measurable and unmeasurable tophi.